HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: ICMAD

This article was originally published in The Rose Sheet

Executive Summary

ICMAD: Requests inclusion "in any discussions that may evolve from the discontinuance of the voluntary reporting of cosmetic product experience" in comments filed with FDA Oct. 15. The Independent Cosmetic Manufacturers and Distributors supports the agency's proposed elimination of the Voluntary Cosmetic Product Experience reporting program, stating that "data resulting from the voluntary filing of these product experience reports...confirm the remarkable safety of cosmetics marketed in the United States." ICMAD adds that the trade group and its members "will continue their commitment to cosmetic product safety." FDA announced its proposal to eliminate the VCPE in the June 12 Federal Register ("The Rose Sheet" June 17, p. 4)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS003372

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel